Core Insights - Novo Nordisk presented findings from the STEP UP phase 3b trial, indicating that Wegovy (semaglutide 2.4 mg and investigational 7.2 mg doses) leads to an average weight loss of 21% and helps achieve treatment targets that lower the risk of obesity-related complications [1][4]. Group 1: Treatment Efficacy - The STEP UP trial showed that a higher percentage of participants receiving Wegovy achieved a BMI of less than 27 and a waist-to-height ratio of less than 0.53, with 19.5% for semaglutide 7.2 mg and 13.2% for semaglutide 2.4 mg compared to 0% for placebo [3][7]. - Participants treated with Wegovy who met both BMI and waist-to-height ratio targets also reached healthy levels for two or more cardiovascular risk factors, including blood pressure, cholesterol, and blood sugar levels [4][7]. Group 2: Health Benefits - The results from the STEP UP trial support the use of BMI and waist-to-height ratio as treatment targets in obesity management, demonstrating that Wegovy not only aids in weight loss but also reduces the risk of obesity-related complications [4][5]. - Over half of the participants who achieved both treatment targets reached healthy levels for all four cardiovascular risk factors, indicating a low risk of cardiovascular disease for those treated with Wegovy [4][5]. Group 3: Regulatory Status - The higher dose of Wegovy (semaglutide 7.2 mg) is currently under review by the European Medicines Agency (EMA) and is expected to receive a regulatory decision around the turn of the year [5][6]. - Novo Nordisk also plans to submit the higher dose for review to the US Food and Drug Administration [5].